Covered recipient · General Payments record
DOUGLAS GLENN YOUNG
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,057.88
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $993.34 | 57 |
| Education | $64.54 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $217.11 | 12 |
| Novo Nordisk Inc | $191.71 | 10 |
| Lilly USA, LLC | $94.49 | 5 |
| PFIZER INC. | $86.97 | 4 |
| Bayer HealthCare Pharmaceuticals Inc. | $68.53 | 4 |
| Merck Sharp & Dohme Corporation | $61.20 | 4 |
| BioDelivery Sciences International, Inc. | $59.12 | 4 |
| AbbVie Inc. | $51.29 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $44.02 | 2 |
| Biohaven Pharmaceuticals, Inc. | $38.01 | 2 |
| E.R. Squibb & Sons, L.L.C. | $31.51 | 2 |
| AstraZeneca Pharmaceuticals LP | $26.55 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $17.46 | 1 |
| Philips Electronics North America Corporation | $17.18 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $13.90 | 1 |
| Amarin Pharma Inc. | $13.83 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.50 | 1 |
| SANOFI-AVENTIS U.S. LLC | $12.50 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DOUGLAS GLENN YOUNG
NPI 1346340296 · CMS profile ID 61209
Allopathic & Osteopathic Physicians / Internal Medicine
SACRAMENTO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $1,057.88 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $22.21 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819067919 | CMS |
| GlaxoSmithKline, LLC. | $19.19 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801640027 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $17.46 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777755019 | CMS |
| Biohaven Pharmaceuticals, Inc. | $12.21 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852661839 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.99 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763471854 | CMS |
| Merck Sharp & Dohme Corporation | $19.83 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848591953 | CMS |
| Biohaven Pharmaceuticals, Inc. | $25.80 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852661837 | CMS |
| Amarin Pharma Inc. | $13.83 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815302029 | CMS |
| GlaxoSmithKline, LLC. | $22.33 | 01/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802934535 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $117.77 | 4 |
| PY2025 | Principal investigator | $900,867.48 | 96 |
| PY2024 | Recipient | $11,436.50 | 17 |
| PY2024 | Principal investigator | $761,077.69 | 77 |
| PY2023 | Recipient | $665.01 | 1 |
| PY2023 | Principal investigator | $496,691.27 | 61 |
| PY2022 | Principal investigator | $524,158.86 | 50 |
| PY2021 | Principal investigator | $470,510.25 | 36 |
| PY2020 | Recipient | $21.90 | 1 |
| PY2020 | Principal investigator | $350,435.53 | 70 |
| PY2019 | Recipient | $4,318.35 | 2 |
| PY2019 | Principal investigator | $498,817.39 | 96 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
100 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $99.00 | 12/30/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246792198 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $400.00 | 12/30/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246792202 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,600.00 | 12/30/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246792206 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,500.00 | 12/30/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246792211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,291.40 | 12/30/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184280704 |
| Principal investigator 1 | Verona Pharma, Inc. | $16,359.90 | 12/19/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891549 |
| Principal investigator 1 | Verona Pharma, Inc. | $29,307.71 | 12/17/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891547 |
| Principal investigator 1 | ModernaTX, Inc. | $5,422.21 | 12/01/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,112.65 | 11/26/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184265539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,112.65 | 11/20/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,075.10 | 11/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184260951 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 11/11/2025 | Non-covered Recipient Entity Northern California Research | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047277 |
| Principal investigator 1 | Verona Pharma, Inc. | $3,500.00 | 11/03/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,805.33 | 10/29/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253758 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 10/28/2025 | Non-covered Recipient Entity Northern California Research | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047275 |
| Principal investigator 1 | ModernaTX, Inc. | $6,354.79 | 10/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,919.45 | 10/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,291.40 | 10/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,139.39 | 10/16/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250829 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $575.00 | 10/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789132 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,500.00 | 10/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789136 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,040.00 | 10/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789141 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $19,684.28 | 10/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,150.46 | 10/08/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184247298 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,239.18 | 10/01/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244469 |
| Principal investigator 1 | Janssen Research & Development, LLC | $53,208.00 | 09/25/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167623 |
| Principal investigator 1 | ModernaTX, Inc. | $2,901.01 | 09/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,848.99 | 09/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184242469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,364.33 | 09/18/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184240670 |
| Principal investigator 1 | Verona Pharma, Inc. | $7,747.59 | 09/17/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68,770.45 | 09/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184236081 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,557.92 | 09/03/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235027 |
| Principal investigator 1 | ModernaTX, Inc. | $2,527.81 | 08/27/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,375.16 | 08/21/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184229793 |
| Principal investigator 1 | Verona Pharma, Inc. | $9,000.00 | 08/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891505 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,800.00 | 08/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891507 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,000.00 | 08/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,343.79 | 08/07/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,857.55 | 07/31/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184222948 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,622.00 | 07/28/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167581 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,415.00 | 07/25/2025 | Non-covered Recipient Entity Northern California Research | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,821.28 | 07/23/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48,093.75 | 07/23/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27,410.40 | 07/23/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184218035 |
| Principal investigator 1 | ModernaTX, Inc. | $4,690.37 | 07/18/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,252.62 | 07/10/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,856.42 | 07/03/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184212645 |
| Principal investigator 1 | ModernaTX, Inc. | $6,534.34 | 06/25/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,856.42 | 06/25/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,126.31 | 06/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184205881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,085.00 | 06/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184205883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,333.45 | 06/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184205885 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,044.80 | 06/04/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,836.98 | 05/26/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198481 |
| Principal investigator 1 | ModernaTX, Inc. | $2,795.11 | 05/23/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,091.00 | 05/20/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167558 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,761.07 | 05/19/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184196315 |
| Principal investigator 1 | ABBVIE INC. | $11,404.00 | 05/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | No dispute reported | 06/30/2026 | 1202484947 |
| Principal investigator 1 | Mylan Inc. | $17,629.00 | 05/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1238884865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,036.80 | 05/12/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,088.90 | 05/12/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194253 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $26,488.00 | 05/07/2025 | Non-covered Recipient Entity Northern California Research | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,619.10 | 05/05/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184192747 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 04/29/2025 | Non-covered Recipient Entity Northern California Research | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,312.87 | 04/28/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190645 |
| Principal investigator 1 | ModernaTX, Inc. | $4,251.62 | 04/25/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964552 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $24.55 | 04/22/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045456 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $85.56 | 04/22/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045458 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $45.00 | 04/22/2025 | Non-covered Recipient Individual | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,973.63 | 04/21/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184185249 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,866.00 | 04/17/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,287.58 | 04/15/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183246 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $60.00 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046480 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $18.30 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046482 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $17.07 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046484 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $22.40 | 04/11/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,543.00 | 04/09/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,428.42 | 04/07/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184181904 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,497.88 | 04/01/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180590 |
| Principal investigator 1 | ModernaTX, Inc. | $4,351.52 | 03/26/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,516.00 | 03/25/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167675 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,320.54 | 03/19/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,467.23 | 03/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184170776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,146.69 | 03/04/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184156638 |
| Principal investigator 1 | ModernaTX, Inc. | $4,351.52 | 02/26/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964540 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,028.72 | 02/25/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184155488 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,437.00 | 02/19/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167566 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,167.45 | 02/18/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154362 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,174.63 | 02/11/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,174.63 | 02/05/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184152508 |
| Principal investigator 1 | Eli Lilly and Company | $22,155.00 | 01/28/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH CORPORATION | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187886064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,992.27 | 01/28/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149806 |
| Principal investigator 1 | ModernaTX, Inc. | $7,805.30 | 01/24/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252964550 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,811.00 | 01/21/2025 | Non-covered Recipient Entity Northern California Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175167600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,997.24 | 01/21/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149148 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,990.06 | 01/14/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184147519 |
| Principal investigator 1 | Eli Lilly and Company | $545.05 | 01/09/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH CORPORATION | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187888028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,023.27 | 01/07/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184146018 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $58,813.74 | 01/03/2025 | Non-covered Recipient Entity NORTH COUNTY CLINICAL RESEARCH | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185540133 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,356.03 | 01/01/2025 | Non-covered Recipient Entity NORTHERN CALIFORNIA RESEARCH | A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis | No dispute reported | 06/30/2026 | 1190299117 |